Initial Circulating CD138 Predicts End-Stage Kidney Disease in Patients with Microscopic Polyangiitis
Yonsei Medical Journal · 2025
DOI: 10.3349/ymj.2024.0457 ↗Kurz gefasst
Fachartikel in der Zeitschrift Yonsei Medical Journal, 2025. Verfasst von Jung Yoon Pyo und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea. Hauptthemen laut MEDLINE: Kidney Failure, Chronic, Syndecan-1, Microscopic Polyangiitis. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eisai Korea, Yuhan.
Abstract (Originalsprache)
PURPOSE: CD138 is a cell surface proteoglycan involved in plasma cell survival and cell adhesion, and can be detected in serum via ectodomain shedding. This study aimed to investigate the clinical utility of circulating CD138 at diagnosis in predicting future progression to end-stage kidney disease (ESKD) in patients with microscopic polyangiitis (MPA). MATERIALS AND METHODS: Sixty-five patients newly diagnosed with MPA were included. Antineutrophil cytoplasmic antibody-associated vasculitis-specific indices and clinical and laboratory data were collected. Circulating CD138 levels were measured from stored sera at the time of diagnosis and a cut-off value for predicting ESKD progression was determined using receiver operating characteristic curve analysis. RESULTS: The median circulating CD138 level at diagnosis was 62.8 ng/mL. Circulating CD138 at diagnosis showed positive correlations with the cross-sectional Birmingham Vasculitis Activity Score, Five-Factor Score, erythrocyte sedimentation rate, C-reactive protein level, and baseline serum creatinine level, while demonstrating a negative correlation with serum albumin level. Overall, 12 (18.5%) of 65 patients progressed to ESKD. The incidence of progression to ESKD was higher in patients with circulating CD138 ≥73.3 ng/mL at diagnosis than in those without (relative risk=10.588). Additionally, patients with circulating CD138 ≥73.3 ng/mL at diagnosis exhibited significantly lower ESKD-free survival rates than those without (p=0.002). CONCLUSION: This study demonstrated that circulating CD138 measured at diagnosis has clinical utility as a biomarker for predicting future progression to ESKD in patients with MPA, and incorporating CD138 measurement at diagnosis may assist in identifying high-risk patients and guiding early therapeutic interventions in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
- Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
- Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Korea.
- Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Korea. sangwonlee@yuhs.ac.
ORCID-Profile: Jung Yoon Pyo, Yong-Beom Park, Sang-Won Lee
Förderung
- Eisai Korea
- Yuhan
Zitieren
APA
Pyo, J. Y., Park, Y. B., & Lee, S. W. (2025). Initial Circulating CD138 Predicts End-Stage Kidney Disease in Patients with Microscopic Polyangiitis. Yonsei Medical Journal. https://doi.org/10.3349/ymj.2024.0457
Vancouver
Pyo JY, Park YB, Lee SW. Initial Circulating CD138 Predicts End-Stage Kidney Disease in Patients with Microscopic Polyangiitis. Yonsei Medical Journal. 2025. doi:10.3349/ymj.2024.0457
BibTeX
@article{Pyo2025,
author = {Pyo, Jung Yoon and Park, Yong-Beom and Lee, Sang-Won},
title = {Initial Circulating CD138 Predicts End-Stage Kidney Disease in Patients with Microscopic Polyangiitis},
journal = {Yonsei Medical Journal},
year = {2025},
doi = {10.3349/ymj.2024.0457}
}
EUVIMED